CA2786664C - Vectors and methods for transducing b cells - Google Patents
Vectors and methods for transducing b cells Download PDFInfo
- Publication number
- CA2786664C CA2786664C CA2786664A CA2786664A CA2786664C CA 2786664 C CA2786664 C CA 2786664C CA 2786664 A CA2786664 A CA 2786664A CA 2786664 A CA2786664 A CA 2786664A CA 2786664 C CA2786664 C CA 2786664C
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- interest
- nucleic acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29352210P | 2010-01-08 | 2010-01-08 | |
| US61/293,522 | 2010-01-08 | ||
| PCT/US2011/020578 WO2011085247A2 (en) | 2010-01-08 | 2011-01-07 | Vectors and methods for transducing b cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2786664A1 CA2786664A1 (en) | 2011-07-14 |
| CA2786664C true CA2786664C (en) | 2020-03-10 |
Family
ID=44306176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2786664A Active CA2786664C (en) | 2010-01-08 | 2011-01-07 | Vectors and methods for transducing b cells |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9074223B2 (https=) |
| EP (1) | EP2521789B1 (https=) |
| JP (1) | JP5873807B2 (https=) |
| CA (1) | CA2786664C (https=) |
| DK (1) | DK2521789T3 (https=) |
| ES (1) | ES2617749T3 (https=) |
| WO (1) | WO2011085247A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014010823B1 (pt) * | 2011-11-07 | 2021-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial |
| WO2014152832A1 (en) | 2013-03-14 | 2014-09-25 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
| US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
| EP3146040B1 (en) * | 2014-05-19 | 2023-03-08 | F. Hoffmann-La Roche AG | Method for producing antibodies using ovine b-cells and uses thereof |
| DK3234107T3 (da) | 2014-12-19 | 2022-10-17 | Immusoft Corp | B-celler til in vivo-levering af terapeutiske midler |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| WO2017143052A1 (en) * | 2016-02-16 | 2017-08-24 | Duke University | Methods for expanding and differentiating b cells for producing antibody |
| BR112019022473A2 (pt) * | 2017-04-27 | 2020-10-20 | Immusoft Corporation | células b para liberação in vivo de agentes terapêuticos e dosagens destas |
| CA3079681A1 (en) * | 2017-10-20 | 2019-04-25 | Fred Hutchinson Cancer Research Center | Systems and methods to produce b cells genetically modified to express selected antibodies |
| EP3765601A1 (en) | 2018-03-16 | 2021-01-20 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| RU2714380C1 (ru) * | 2018-12-28 | 2020-02-14 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ получения цитотоксических т-лимфоцитов, экспрессирующих химерные рецепторы |
| KR20210152536A (ko) * | 2019-04-12 | 2021-12-15 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 조절 b 세포의 생산 방법 및 이의 용도 |
| EP4097144A4 (en) * | 2020-01-28 | 2024-02-28 | University of Southern California | Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules |
| WO2022040202A1 (en) * | 2020-08-17 | 2022-02-24 | Northwestern University | B-cell based immunotherapy for the treatment of glioblastoma and other cancers |
| WO2025106856A1 (en) | 2023-11-15 | 2025-05-22 | Immusoft Corporation | Migratory modified differentiated b cells for cancer therapy |
| WO2025147573A2 (en) | 2024-01-05 | 2025-07-10 | Immusoft Corporation | Glp-1 expressing modified b cells for the treatment of metabolic disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| KR100807016B1 (ko) * | 2000-06-01 | 2008-02-25 | 가부시키가이샤 디나벡크 겐큐쇼 | 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터 |
| JP4238138B2 (ja) * | 2001-12-22 | 2009-03-11 | ４−アンチボディ アーゲー | 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。 |
| US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
| EP1975239A1 (en) * | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| US8133727B2 (en) | 2008-11-21 | 2012-03-13 | California Institute Of Technology | In vitro human B lymphopoiesis culture system |
-
2011
- 2011-01-07 US US13/520,921 patent/US9074223B2/en active Active
- 2011-01-07 JP JP2012548181A patent/JP5873807B2/ja active Active
- 2011-01-07 EP EP11732231.3A patent/EP2521789B1/en active Active
- 2011-01-07 CA CA2786664A patent/CA2786664C/en active Active
- 2011-01-07 WO PCT/US2011/020578 patent/WO2011085247A2/en not_active Ceased
- 2011-01-07 ES ES11732231.3T patent/ES2617749T3/es active Active
- 2011-01-07 DK DK11732231.3T patent/DK2521789T3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2521789A2 (en) | 2012-11-14 |
| WO2011085247A2 (en) | 2011-07-14 |
| DK2521789T3 (en) | 2017-03-27 |
| EP2521789A4 (en) | 2013-08-21 |
| JP2013516194A (ja) | 2013-05-13 |
| CA2786664A1 (en) | 2011-07-14 |
| EP2521789B1 (en) | 2016-12-14 |
| US9074223B2 (en) | 2015-07-07 |
| JP5873807B2 (ja) | 2016-03-01 |
| WO2011085247A4 (en) | 2011-12-29 |
| US20130143267A1 (en) | 2013-06-06 |
| WO2011085247A3 (en) | 2011-11-10 |
| ES2617749T3 (es) | 2017-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230081163A1 (en) | B cells for in vivo delivery of therapeutic agents | |
| US20250243459A1 (en) | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors | |
| CA2786664C (en) | Vectors and methods for transducing b cells | |
| WO2018201071A1 (en) | B cells for in vivo delivery of therapeutic agents and dosages thereof | |
| CA2971430C (en) | B cells for in vivo delivery of therapeutic agents | |
| HK1178934B (en) | Vectors and methods for transducing b cells | |
| HK1178934A (en) | Vectors and methods for transducing b cells | |
| HK1220230B (en) | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors | |
| HK1245834B (en) | B cells for in vivo delivery of therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160106 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241207 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241207 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |